Maryland State Retirement & Pension System Acquires New Position in Revvity, Inc. (NYSE:RVTY)

Maryland State Retirement & Pension System purchased a new stake in shares of Revvity, Inc. (NYSE:RVTY - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 9,639 shares of the company's stock, valued at approximately $1,054,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of RVTY. Parkside Financial Bank & Trust bought a new position in shares of Revvity in the fourth quarter valued at approximately $25,000. Gladius Capital Management LP lifted its position in Revvity by 84.1% during the 3rd quarter. Gladius Capital Management LP now owns 232 shares of the company's stock worth $26,000 after acquiring an additional 106 shares during the last quarter. CENTRAL TRUST Co bought a new stake in Revvity during the fourth quarter valued at about $27,000. Benjamin F. Edwards & Company Inc. acquired a new stake in shares of Revvity in the fourth quarter valued at about $27,000. Finally, ORG Partners LLC bought a new position in shares of Revvity in the fourth quarter worth about $32,000. Hedge funds and other institutional investors own 86.65% of the company's stock.

Revvity Price Performance

RVTY stock traded up $0.46 during trading on Friday, hitting $104.80. 607,943 shares of the stock traded hands, compared to its average volume of 833,467. The company has a current ratio of 2.23, a quick ratio of 1.92 and a debt-to-equity ratio of 0.40. The stock has a market cap of $12.95 billion, a price-to-earnings ratio of 86.61, a P/E/G ratio of 2.62 and a beta of 1.09. Revvity, Inc. has a one year low of $79.50 and a one year high of $131.96. The company has a 50 day simple moving average of $104.24 and a 200 day simple moving average of $101.32.

Revvity (NYSE:RVTY - Get Free Report) last issued its quarterly earnings data on Monday, April 29th. The company reported $0.98 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.94 by $0.04. Revvity had a return on equity of 7.37% and a net margin of 5.49%. The firm had revenue of $649.90 million during the quarter, compared to the consensus estimate of $646.83 million. During the same quarter in the previous year, the company posted $1.01 EPS. The business's revenue for the quarter was down 3.7% compared to the same quarter last year. Equities analysts expect that Revvity, Inc. will post 4.66 EPS for the current fiscal year.

Revvity Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, August 9th. Shareholders of record on Friday, July 19th will be issued a dividend of $0.07 per share. The ex-dividend date is Friday, July 19th. This represents a $0.28 annualized dividend and a yield of 0.27%. Revvity's dividend payout ratio is currently 23.14%.

Analyst Upgrades and Downgrades

Several brokerages have commented on RVTY. Barclays lifted their price target on Revvity from $92.00 to $105.00 and gave the stock an "equal weight" rating in a research report on Thursday, January 25th. TD Cowen upped their target price on shares of Revvity from $123.00 to $130.00 and gave the company a "buy" rating in a research note on Tuesday, April 30th. Stifel Nicolaus raised their price target on shares of Revvity from $95.00 to $110.00 and gave the stock a "hold" rating in a research report on Friday, February 2nd. KeyCorp increased their target price on shares of Revvity from $110.00 to $126.00 and gave the company an "overweight" rating in a research note on Friday, February 2nd. Finally, Robert W. Baird lifted their target price on Revvity from $126.00 to $127.00 and gave the stock an "outperform" rating in a research report on Tuesday, April 30th. Six research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $118.17.

About Revvity

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.